Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Cut to Hold at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

KNSA has been the topic of several other research reports. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Finally, Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded down $0.43 during mid-day trading on Friday, hitting $27.24. 701,980 shares of the company's stock were exchanged, compared to its average volume of 549,708. The stock's 50-day moving average is $27.09 and its 200-day moving average is $22.74. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $30.69. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -108.96 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The firm's revenue was up 72.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) earnings per share. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 18,299 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $28.80, for a total transaction of $527,011.20. Following the completion of the sale, the chief financial officer owned 27,009 shares in the company, valued at $777,859.20. This represents a 40.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eben Tessari sold 17,300 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $28.28, for a total value of $489,244.00. Following the sale, the chief operating officer directly owned 61,563 shares of the company's stock, valued at approximately $1,741,001.64. This represents a 21.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 440,863 shares of company stock valued at $12,101,029. Corporate insiders own 53.48% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares in the last quarter. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $42,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at about $61,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.